Drug intelligence / Profile preview

TEDDI-R

Development stage: Unknown
Lead developer: National Cancer Institute
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral, Intrathecal

Overview

TEDDI-R is a combination immunochemotherapy regimen consisting of Temozolomide, Etoposide, Doxil (liposomal doxorubicin), Dexamethasone, Ibrutinib, and Rituximab. It was developed for the treatment of primary and secondary central nervous system lymphomas. The regimen combines targeted therapy (ibrutinib) with conventional chemotherapy agents and immunotherapy (rituximab) to address aggressive lymphomas involving the central nervous system, which typically have poor prognosis with standard treatments.

Other names: TEDDi-RMini-TEDDI-RDA-TEDDI-R

Targets

CD20 (B-lymphocyte antigen CD20)BTK (Bruton tyrosine kinase)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNA

Beyond the preview

Go deeper on TEDDI-R.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TEDDI-R.

Explore the full profile